BioMarin Pharmaceutical Inc. (BMRN) Thursday said it expects fiscal year 2009 GAAP loss in the range of $8.0 million to $4.0 million. Non-GAAP net income is forecast in the range of $39.8 million to $43.8 million. Total net product revenues are forecast in the range of $306 million to $320 million.
Street analysts expect a loss of $0.04 per share on revenues of $323.04 million.
For the fiscal year 2010, the company expects GAAP net income in the range of $2 million to $12 million. Non-GAAP net income is expected to range from $39 million to $49 million. Total net product revenues for the year are forecast to range from $368 million to $398 million.
Street analysts expect earnings of $0.23 per share on revenues of $398.27 million.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.